Factor XI Inhibitors: Anticoagulation with Minimal Bleeding?
The development of new antithrombotic agents is fundamentally driven by the need to effectively prevent dangerous blood clots (thrombosis) while
Read More
The development of new antithrombotic agents is fundamentally driven by the need to effectively prevent dangerous blood clots (thrombosis) while
Read More
Venous thromboembolism (VTE) encompasses pulmonary embolism and deep vein thrombosis. These conditions carry a significant risk of recurrence, particularly following
Read More
Obesity is a known risk factor for venous thromboembolism. But treating blood clots in overweight people poses another challenge. In
Read More
Anticoagulation works in most people. In fact, the rate of anticoagulation failure is quite low. For this reason, if a
Read More
Your patient suffered a venous thromboembolic event. It might have been a pulmonary embolism or a deep vein thrombosis. Now
Read More
Anticoagulation in renal failure poses two challenges. First, the kidneys are involved in the metabolism of many anticoagulants. And second,
Read More
Asundexian is an oral inhibitor of activated factor XI. Obviously, a deficiency of factor XI causes a rare type of
Read More
NSAIDs are anti-inflammatory medications. The most common reasons to take them are chronic joint pain. Unfortunately, many patients who require
Read More